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Menopausal therapy and protection 
against coronary heart disease 
To the Editor: The South African Menopause Society (SAMS) 
statement on menopausal therapy1 varies little from their 
previous publication,2 except for proper definition of the 
indications and contraindications, and some changes in the 
position statement. It now includes a statement that hormone 
therapy (HT) may offer primary protection against coronary 
heart disease (CHD) if started soon after menopause. They 
base this ‘on the assumption that estrogen offers protection 
only when the arterial endothelium is still intact’ and state that 
this ‘is supported by epidemiological studies, animal models 
and the ET arm of the WHI’.  SAMS is trying to promote a 
concept that may not be true. Epidemiological and animal 
studies do not always predict or correlate with the outcomes of 
proper controlled double-blind clinical trials, and no such trial 
confirms this proposal.  
It is folly for SAMS to promote this concept. The recent 
Evidence-Based Guidelines for Cardiovascular Disease 
Prevention in Women: 2007 Update3 does not mention using 
HT for prevention, once again classifying it as a class III 
intervention (not useful/effective and may be harmful), and 
states that hormone therapy and selective estrogen-receptor 
modulators should not be used for the primary or secondary 
prevention of cardiovascular disease.
A misconception among the medical fraternity is the 
notion of ‘an intact arterial endothelium’. Atherosclerosis 
is a process that starts early in life and tends to be detected 
only when patients present with complications, women 
being no exception. Not every patient is subjected to invasive 
tests to determine whether they have an ‘intact’ arterial 
endothelium or not.  Recently two ‘cardioprotective’ drugs 
(both involved in properly controlled clinical outcome trials) 
have been discredited. The first was torcetrapib, a cholesterol 
ester transfer protein inhibitor that significantly raises 
high-density lipoprotein cholesterol (HDL-C). It showed 
no advantage in limiting coronary disease progression as 
ascertained by intravascular ultrasound, and was associated 
with worse cardiovascular and mortality outcomes than statin 
monotherapy.4 Of note is that the pattern of cholesterol change 
seen with this drug is similar to the profile in women on 
HT, i.e. an increase in HDL-C and a decrease in low-density 
lipoprotein cholesterol (LDL-C), which brings up the question 
of what is good HDL-C. All the hormone therapy trials 
achieved this lipid profile, but none have shown corresponding 
positive clinical outcomes – irrespective of whether they 
were secondary or primary prevention studies. The second 
discredited drug group is the glitazones, used in the treatment 
of diabetes mellitus, which have shown similar trends in 
cholesterol lowering. However, recently the US Food and Drug 
Administration warned that they cause increased fractures 
in women on long-term therapy. There is also concern that 
one of these agents, rosiglitazone, may be associated with a 
potentially significant increase in the risk of heart attack and 
heart-related deaths.5
Risk stratification of women is a problem. The Reynolds Risk 
Score6 validated and demonstrated highly improved accuracy 
of two clinical algorithms for global cardiovascular risk 
prediction in women. It reclassified 40 - 50% of women, who 
on traditional risk scoring were deemed to be at intermediate 
risk, into higher- or lower-risk categories, but predominantly 
into a higher-risk group. The main difference compared with 
the Framingham Risk Score is the addition of high-sensitivity 
C-reactive protein (hs-CRP) and family history. A concern 
associated with HT is that it causes an increase in hs-CRP, 
which itself may be a risk factor for the development of CHD. 
One of the cornerstones of medical treatment is to ‘do no 
harm’.  Until there is solid evidence that HT is protective in the 
primary prevention of CHD, colleagues are strongly advised 
to not follow the advice of the recent consensus position 
statement.
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Dr De Villiers replies: Dr Rapeport disagrees with the 
statement that HT may offer primary protection against CHD 
if started soon after menopause. She does not, however, 
offer any facts based on clinical trial evidence to support her 
argument. Since submission of the revised SAMS statement 
in January 2007, two new publications by none other than the 
Women’s Health Study (WHI) investigators strongly support 
our viewpoint.
A secondary analysis of the combined estrogen alone (ET) 
and combination therapy (EPT) arms of the WHI concluded 
that women who initiated hormone therapy closer to 
menopause tended to have reduced CAD risk compared 
with the increase in CAD among women more distant from 
menopause.1 The same investigators revealed in a secondary 
analysis of the ET arm of the WHI that patients treated with 
estrogen in the age group 50 - 59 years, when compared with 
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placebo-treated patients, were 42 - 61% less likely to have 
significant arterial calcification (as measured by computed 
tomography).2 These publications are in stark contrast to earlier 
publications by the same investigators that implied HT as a 
cause of CAD, without taking into account that this did not 
apply to the typical patient, who initiates HT at the age of  
50 - 59 years.3
Dr Rapeport further falsely assumes that SAMS promotes 
the use of HT for the prevention of CAD, even though it is 
not included in the list of approved indications in the revised 
guidelines. We maintain our position that if the only aim of 
treatment is protection against CAD, HT is an inappropriate 
choice in view of other proven methods. However, it is 
important to be able to assure the patient in the age group 50 - 
59 years, who starts HT for the control of vasomotor symptoms 
or the prevention or treatment of osteoporosis, not only that 
HT will not cause CAD, but that protection can be expected. 
This also needs to be taken into account when deciding on 
termination of treatment.
We stand by our statement that the initiation of HT for the 
indications as provided is safe for the patient in the age group 
50 - 59 years and that the small risk of any complication can be 
further reduced by using the lowest effective dose.
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‘Opi-phobia’ among doctors leads to  
unnecessary suffering
To the Editor: Francois Venter and Chris Bateman are to be 
commended on this piece.1 Basic training of South African 
doctors and nurses in palliative care has been poor.  Therefore 
few have raised their voices to improve palliative care, despite 
the great need for it in a developing country where many 
patients present with far advanced disease.  This applies 
particularly to people with HIV because of denial and stigma.
An important step towards the development of good general 
palliative care in Australia and the UK has been the formation 
of departments of palliative care in teaching hospitals, through 
which all students must rotate during their training.  I suggest 
that pharmacology students also have a short rotation.  With 
the enormous need for such care, it seems an urgent priority to 
establish such departments in all our teaching hospitals. These 
should also bring past graduates up to speed in this discipline.
Another serious public sector hospital problem is the lack 
of effective links between district hospitals and community 
structures offering home-based care.  Too often, medical 
staff end up saying to patients, ‘There is nothing more that 
we can do for you’, because the doctor has decided cure is 
not possible.  In most cases, no thought is given to linking 
patients to community carers, or to empowering the carers 
with medications to reduce the suffering of their last days. No 
help in controlling symptoms is provided to home-based 
carers who appeal to district clinics when the scheduled 
drugs needed are not available to clinic staff.  This has two 
effects. Firstly, hospital staff are never really confronted with 
the patient’s palliative care needs, so they never grow in that 
expertise. Secondly, there is an assumption that palliative care 
in HIV is simple (which it is not), just as the rest of the medical 
care of people with HIV is difficult and requires considerable 
experience and expertise.
A solution to this problem could be the development of 
palliative care facilities in every district hospital, staffed by 
medical and nursing staff who are part of the training team 
of home-based carers in the district.  They could assess the 
patient’s palliative needs, access the necessary medications, 
and link the patient and family to a designated carer, or non-
governmental organisation.  They should also identify patients 
with HIV wrongly consigned to terminal care when they have 
a manageable infectious condition.  Such a facility could have 
regular follow-up clinics in each of the district clinics, and be 
empowered to carry and dispense the necessary scheduled 
drugs. This should be a high-priority project for co-operation 
between district health services and the medical staff of every 
district hospital, including those in metropolitan centres 
serving rural communities.
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Achieving the Millennium Develop-
ment Goals in sub-Saharan Africa  
To the Editor: The UN has released a mid-term report on 
progress towards achieving the Millennium Development 
Goals (MDG), eight pro-poor goals contained in the 
Millennium Declaration of 2000, to be achieved by 2015.1 
It paints a gloomy picture of health in sub-Saharan Africa. 
Child mortality rates declined globally, but the improvement 
was uneven, with sub-Saharan Africa recording the highest 
rate and the slowest pace of progress. In 1990 and 2005 in 
sub-Saharan Africa, 185 and 166 children respectively died, 
mainly from preventable causes, before their 5th birthday for 
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